Metraipolis › archive › dc_0fa212029dde

Initial Patient Characteristics Associated With Ineligibility for Second-Line Therapy After Progression on First-Line Osimertinib in EGFR-Mutated Non-Small… — Europe PMC PMID:41243674

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41243674
DOI
10.1111/1759-7714.70192
License (as archived)
solo-consultazione
Archived
2026-11-08T20:33:33.389Z
SHA-256 of the archived text
5d3e4c89321d9ad5a2af762da1e0da0e359e284bb5a5f5406c1e83a3cd4e3799
Stable URL of this page
https://metraipolis.com/documento/dc_0fa212029dde

How to cite

Initial Patient Characteristics Associated With Ineligibility for Second-Line Therapy After Progression on First-Line Osimertinib in EGFR-Mutated Non-Small… — Europe PMC PMID:41243674 — Europe PMC (en), https://europepmc.org/article/MED/41243674 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_0fa212029dde (Metraipolis archive dc_0fa212029dde, sha256 5d3e4c89321d9ad5a2af762da1e0da0e359e284bb5a5f5406c1e83a3cd4e3799)
BibTeX
@misc{dc0fa212029dde,
  title = {Initial Patient Characteristics Associated With Ineligibility for Second-Line Therapy After Progression on First-Line Osimertinib in EGFR-Mutated Non-Small… — Europe PMC PMID:41243674},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41243674},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_0fa212029dde; sha256 5d3e4c89321d9ad5a2af762da1e0da0e359e284bb5a5f5406c1e83a3cd4e3799},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41243674. Agents can read the archived copy with the MCP tool read_document.